EUVIMEDEUVIMED entdecken
Crossref

A model for predicting poor survival in patients with cirrhosis undergoing portosystemic shunt embolization

Won-Mook Choi, Seo Yeon Yoo, Jong-In Chang, Seungbong Han, Young Seok Kim iD, Dong Hyun Sinn iD, Sang Hyun Choi iD, Dong Il Gwon, Young-Suk Lim iD

Journal of Gastroenterology and Hepatology · 2023

DOI: 10.1111/jgh.16280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2023. Verfasst von Won-Mook Choi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Portasystemic Shunt, Transjugular Intrahepatic, End Stage Liver Disease, Esophageal and Gastric Varices, Hepatic Encephalopathy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Evidence-based Healthcare Collaborating Agency, National Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Portosystemic shunt embolization (PSSE) is a promising treatment for hepatic encephalopathy (HEP) and gastric varix (GV) in cirrhotic patients with a spontaneous portosystemic shunt. However, PSSE may worsen portal hypertension causing hepatorenal syndrome, liver failure, and mortality. This study aimed to develop and validate a prognostic model that helps identify patients with a risk of poor short‐term survival after PSSE.

Methods

We included 188 patients who underwent PSSE for recurrent HEP or GV at a tertiary center in Korea. To develop a prediction model for 6‐month survival after PSSE, Cox proportional‐hazard model was used. The developed model was validated in a separate cohort of 184 patients from two other tertiary centers.

Results

In multivariable analysis, the 1‐year overall survival after PSSE was significantly associated with baseline levels of serum albumin, total bilirubin, and international normalized ratio (INR). We therefore developed the albumin‐bilirubin‐INR (ABI) score by assigning 1 point each for albumin < 3.0 g/dL, total bilirubin ≥ 1.5 mg/dL, and INR ≥ 1.5. Time‐dependent areas under the curve of the ABI score for predicting 3‐month and 6‐month survival were 0.85 and 0.85 in the development cohort and 0.83 and 0.78 in the validation cohort, indicating good discrimination performance. The ABI score showed a better discrimination and calibration performance than the model for end‐stage liver disease and the Child–Pugh scores, especially in high‐risk patients.

Conclusions

The ABI score is a simple prognostic model that helps decide whether to proceed with PSSE for the prevention of HEP or GV bleeding in patients with spontaneous portosystemic shunt.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Portasystemic Shunt, Transjugular IntrahepaticEnd Stage Liver DiseaseEsophageal and Gastric VaricesHepatic EncephalopathyHumansSeverity of Illness IndexLiver CirrhosisGastrointestinal HemorrhageSerum AlbuminBilirubinRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

BRTOPARTOhepatic encephalopathyspontaneous portosystemic shuntvarix

Substanzen

Serum AlbuminBilirubin

Autor:innen und Institutionen

  • Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Department of Gastroenterology, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Republic of Korea.
  • Department of Biostatistics, Korea University College of Medicine, Seoul, Republic of Korea.
  • Department of Internal Medicine, Division of Gastroenterology and Hepatology, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Republic of Korea.
  • Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Young Seok Kim, Dong Hyun Sinn, Sang Hyun Choi, Young-Suk Lim

Förderung

  • National Evidence-based Healthcare Collaborating Agency
  • National Cancer Center

Zitieren

APA

Choi, W. M., Yoo, S. Y., Chang, J. I., Han, S., Kim, Y. S., Sinn, D. H., Choi, S. H., Gwon, D. I., & Lim, Y. S. (2023). A model for predicting poor survival in patients with cirrhosis undergoing portosystemic shunt embolization. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16280

Vancouver

Choi WM, Yoo SY, Chang JI, Han S, Kim YS, Sinn DH, et al. A model for predicting poor survival in patients with cirrhosis undergoing portosystemic shunt embolization. Journal of Gastroenterology and Hepatology. 2023. doi:10.1111/jgh.16280

BibTeX
@article{Choi2023,
  author = {Choi, Won-Mook and Yoo, Seo Yeon and Chang, Jong-In and Han, Seungbong and Kim, Young Seok and Sinn, Dong Hyun and Choi, Sang Hyun and Gwon, Dong Il and Lim, Young-Suk},
  title = {A model for predicting poor survival in patients with cirrhosis undergoing portosystemic shunt embolization},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2023},
  doi = {10.1111/jgh.16280}
}
Kostenlos starten →